International Journal of Hematology and Oncology 2020, Vol 30, Num 3 Page(s): 204-216
CLINICAL CHARACTERISTICS AND ADJUVANT CHEMOTHERAPY RESULTS OF DUKES STAGES B2 AND C COLORECTAL CANCER PATIENTS: 10 YEARS ERCIYES UNIVERSITY EXPERIENCE

ÖZLEM ER1, HASAN S. COŞKUN1, MUSTAFA ALTINBAŞ1, BÜLENT ESER1, MUSTAFA ÇETİN1, ALİ ÜNAL1

Erciyes Üniversitesi Tıp Fakültesi, Medikal Onkoloji Bilim Dalı, Kayseri

Keywords: colorectal carcinoma, adjuvant chemotherapy, prognosis
One hundred fifty three colorectal cancer patients in Dukes B2 and C stage, followed in Erciyes University Medical Faculty Oncology Department between January 1990- December 1999 were evaluated retrospectively. Ninety patients (58.8%) were male and 63 female (41.2%). Mean follow-up period was 22 months. According to Dukes staging sys tem, 95 patients (62%) were in Dukes B2, 8 (%5.3) in Dukes C1, 50 (%32.7) in Dukes C2. Adjuvant fluorouracil based chemotherapy regimens were administered to 152 patients. Distant metastases in 31 patients and local relapse in 13 patients developed during follow-up. Overall and disease free survival were calculated as 63.47±4.71 and 41.58±3.96 months respectively. Disease free survival for Dukes B2 and C stage patients were calculated as 66.38 ±6.38 and 27.72±3.23 months, there was statistically significant difference (p=0.006). Disease free survival was calculated as 24.16±4.42 months in mucinous and signet ring cell carcinomas and 48.46+6.12 months in differentiated adenocarcinomas (p=0.05). There was no statistically significant difference in overall and disease free survival according to patients' age, tumor localization and adjuvant chemotherapy regimens. Stage of colorectal cancer is one of the most important determinants of prognosis. Studies for prevention of this disease, diagnosis in early stage and close follow-up are important.